|
|
All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. www.magnetic magic.com the panel seemed to be in agreement that the statistics indicated a significant reduction in ige and that a quantitative drop in symptoms was demonstrated. in 1992, belen anibarro, md, studied five children with asthma with metabisulfite magic.com intolerance confirmed by oral challenge testing. the test was repeated after premedication with 1.5 mg of oral cyanocobalamin. in four of the five patients treated, bronchospasm did not www.magnetic and magic.com develop in the second metabisulfite challenge.6 in 1992 in el paso, tx a randomized, double-blind, placebo controlled study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. the average www.magnetic ige level of the placebo magic.com treated subjects remained essentially flat, while www.magnetic the average ige level for active treated subjects was reduced significantly from baseline to day 30.7 in 1993 in el paso, tx, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days 365 to 395 (the same period, one year after the first set of symptom diaries). the active group had mean symptom scores showing statistically significant decreases from 1992 magic.com to 1993. www.magnetic the placebo group had increased symptoms in 1993. (the relevant pollen counts at the study site in 1993 magic.com were much higher than www.magnetic in 1992, leading to expectation of higher symptoms.)7 studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are magic.com directly metabolized in the liver. when b12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. it is during this first pass in its native form that it is believed to www.magnetic exert its therapeutic effect. clinical research: "the magic.com and www.magnetic world health organization (who) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, magic.com eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which ige-mediated allergy may be involved."1 in 1988, asthma and allergic rhinitis www.magnetic subjects were treated with b12. total ige, specific ige and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. eight of the 9 subjects had reduced ige. 2 in 1989 open label magic.com studies at two sites in riverside county, ca in 1989. sixteen of the 17 subjects had lowered ige www.magnetic and magic.com levels from day 0 to day 30.3
|